Andere Sprachen MaxCyte, Inc.

Aktien

Markt geschlossen - London S.E. Andere Börsenplätze 17:35:02 31.05.2024			% 5 Tage	% 1. Jan.
370 ^GBX	-.--%		+1.37%	+4.96%

22.05.	MaxCyte schließt mit Legend Biotech eine Vereinbarung über die Lieferung von Technologien ab	AN
22.05.	MaxCyte unterzeichnet Lizenzvertrag mit Legend Biotech für Zelltherapieprogramm	MT

MaxCyte inks deal with Legend Biotech for tech supply	22.05.
MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program	22.05.
MaxCyte, Inc. Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development	22.05.
MaxCyte Shares Rise Sharply After Q1 Results Beat	08.05.
MaxCyte shares rise amid double-digit revenue increase	08.05.
Earnings Flash (MXCT.L) MAXCYTE Posts Q1 Revenue $11.3M	08.05.
MaxCyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07.05.
Transcript : MaxCyte, Inc., Q1 2024 Earnings Call, May 07, 2024	07.05.
Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024	07.05.
Jefferies cuts AJ Bell; Deutsche likes ConvaTec	03.05.
MaxCyte inks deal with Be Bio; Orcadian firms farmout	02.04.
MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines	02.04.
MAXCYTE, INC. : BTIG toujours positif	13.03.
MaxCyte loss widens in 2023 as core revenue declines 25%	13.03.
MaxCyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12.03.
Transcript : MaxCyte, Inc., 2023 Earnings Call, Mar 12, 2024	12.03.
MaxCyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12.03.
MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024	12.03.
EARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profit	05.03.
MaxCyte Reaffirms Fiscal 2023 Revenue Guidance	04.03.

Keine Ergebnisse zu dieser Suche